Exploring the use of adalimumab for patients with moderate Crohn's disease: Subanalyses from induction and maintenance trials

This analysis suggests that moderate CD patients can be treated effectively with adalimumab, and supports using CRP to identify moderate CD patients at greatest risk of disease progression.